Visit Contract Pharma
at Stand No. 1G97

Almac Passes MHRA Inspection at Charnwood Facilities


Can develop, make and pack non-potent and potent, solid orals for clinical trials and commercial supply

Almac Group has successfully completed an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its new Pharmaceutical Development & Manufacturing facilities at Charnwood Campus, in Loughborough England.
In November 2015, the company began an expansion of its pharmaceutical development and manufacturing services with the acquisition of a significant proportion of the 70-acre Charnwood Campus, a science and technology park. The facilities have since undergone significant investment both in building enhancements and the installation and validation of new processing and analytical technology.
The successful inspection provides the necessary licenses to develop, manufacture and pack non-potent and potent, solid oral drug products for clinical trials and commercial supply at the site, with the new facility complementing the existing development & GMP services offered from the company’s Craigavon NI headquarters.
Trevor Clarke, global head of Quality Systems said, “We are extremely pleased with the successful roll-out of our Global Quality Management System to the new Charnwood site. This positive endorsement by the MHRA provides our clients with increased capacity governed by the same pharmaceutical quality system which they are already familiar with at our existing sites in Craigavon, Northern Ireland and Audubon, PA.”